Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$129.9 million.

  • SAB Biotherapeutics' Cash from Investing Activities fell 1116705.45% to -$129.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.7 million, marking a year-over-year decrease of 41809.25%. This contributed to the annual value of -$12.0 million for FY2024, which is 773363.04% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Cash from Investing Activities of -$129.9 million as of Q3 2025, which was down 1116705.45% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Cash from Investing Activities peaked at $11.2 million during Q2 2024, and registered a low of -$129.9 million during Q3 2025.
  • Its 5-year average for Cash from Investing Activities is -$7.6 million, with a median of -$117754.0 in 2022.
  • The largest annual percentage gain for SAB Biotherapeutics' Cash from Investing Activities in the last 5 years was 4955696.09% (2024), contrasted with its biggest fall of 14712632.39% (2024).
  • SAB Biotherapeutics' Cash from Investing Activities (Quarter) stood at -$2.4 million in 2021, then skyrocketed by 95.01% to -$117754.0 in 2022, then soared by 42.37% to -$67864.0 in 2023, then surged by 13849.21% to $9.3 million in 2024, then tumbled by 1491.84% to -$129.9 million in 2025.
  • Its Cash from Investing Activities stands at -$129.9 million for Q3 2025, versus $5.2 million for Q2 2025 and $4.7 million for Q1 2025.